GENB.US Generate Biomedicines, Inc. Common Stock

Healthcare Biotechnology USA Stocks
12.07 USD
Close of Nov 14, 2026
11.00 22.67
Market cap
USD 1.55B
P/E
-
P/B
3.53x
ROE
-75.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GENB.US undervalued?

Graham number

The Graham number of Generate Biomedicines, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Generate Biomedicines, Inc. Common Stock fundamental analysis

No fundamental analysis for Generate Biomedicines, Inc. Common Stock yet.

Generate Biomedicines, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Generate Biomedicines, Inc. Common Stock

Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer mono…

Full company profile